Inflammatory Response in COVID-19 Patients Resulting from the Interaction of the Inflammasome and SARS-CoV-2 by 구본녀
 International Journal of 
Molecular Sciences
Review
Inflammatory Response in COVID-19 Patients Resulting from
the Interaction of the Inflammasome and SARS-CoV-2
So Yeong Cheon 1,* and Bon-Nyeo Koo 2,3,*


Citation: Cheon, S.Y.; Koo, B.-N.
Inflammatory Response in COVID-19
Patients Resulting from the
Interaction of the Inflammasome and
SARS-CoV-2. Int. J. Mol. Sci. 2021, 22,
7914. https://doi.org/10.3390/
ijms22157914
Academic Editors: Young-Su Yi and
Tae Jin Lee
Received: 27 June 2021
Accepted: 23 July 2021
Published: 24 July 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Biotechnology, College of Biomedical & Health Science, Konkuk University,
Chungju 27478, Korea
2 Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul 03722, Korea
3 Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul 03722, Korea
* Correspondence: sycheon14@kku.ac.kr (S.Y.C.); koobn@yuhs.ac (B.-N.K.); Tel.: +82-43-840-3616 (S.Y.C.);
+82-2-2228-2420 (B.-N.K.)
Abstract: The outbreak of the coronavirus disease 2019 (COVID-19) began at the end of 2019. COVID-
19 is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and
patients with COVID-19 may exhibit poor clinical outcomes. Some patients with severe COVID-19
experience cytokine release syndrome (CRS) or a cytokine storm—elevated levels of hyperactivated
immune cells—and circulating pro-inflammatory cytokines, including interleukin (IL)-1β and IL-
18. This severe inflammatory response can lead to organ damage/failure and even death. The
inflammasome is an intracellular immune complex that is responsible for the secretion of IL-1β and
IL-18 in various human diseases. Recently, there has been a growing number of studies revealing
a link between the inflammasome and COVID-19. Therefore, this article summarizes the current
literature regarding the inflammasome complex and COVID-19.
Keywords: coronavirus disease 2019; severe acute respiratory syndrome coronavirus 2;
inflammasome; cytokines
1. Introduction
The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection [1]. Some individuals infected with
SARS-CoV-2 have no symptoms, while some experience severe fever, pneumonia, and
even acute respiratory distress syndrome (ARDS) [1]. SARS-CoV-2, which is transmitted
via respiratory droplets, replicates in the lower respiratory tract and aggravates the in-
flammatory response, thereby inducing pneumonia and damage in the airway [2]. Some
patients with COVID-19 exhibit immune disturbances such as cytokine release syndrome
(CRS) and macrophage activation syndrome (MAS) [3,4]. Hyper-cytokinemia, i.e., the
increase in pro-inflammatory and anti-inflammatory cytokine levels, occurs in severe cases.
CRS or the ‘cytokine storm’ contributes to organ damage/failure and death [3,4]. This
cytokine storm was recently shown to be possibly caused by the S1 subunit of the SARS-
CoV-2 spike (S) protein [5]. Furthermore, COVID-19 patients with severe respiratory failure
show MAS or immune dysregulation, characterised by hyperactivated monocytes, CD4+
lymphopenia, B lymphopenia, and natural killer (NK) cytopenia [3]. COVID-19 patients
are also reported to show CD4+ lymphopenia; CD8+ lymphopenia; and higher levels of
cytokines such as interleukin (IL)-6, IL-10, and tumor necrosis factor alpha (TNF-α) [6].
Based on these studies, serious immunological features of patients with COVID-19 have
been reported.
There have been a growing number of studies on inflammasome activation induced
by SARS-CoV-2 infection and COVID-19 severity in patients [2,7]. In particular, the
SARS-CoV-2 S protein primes and drives the activation of the nucleotide-binding oligomeri-
sation domain (NOD)-like receptor family pyrin domain containing 3 (NLRP3) inflam-
masome, and the SARS-CoV-2 S1 protein triggers inflammasome activity alone [8,9]. The
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inflammasome is a macromolecular immune complex in cells, and it is involved in the extra-
cellular release of IL-1β and IL-18 as well as in pyroptotic cell death [10]. Aberrant inflam-
masome activation is related to the pathogenesis or pathophysiology of various diseases
such as autoimmune diseases, infectious diseases, and neurodegenerative diseases [11].
More importantly, these abnormally activated inflammasomes and inflammasome-driven
cytokines are observed in patients with COVID-19. Therefore, in this review, we focused
on the inflammatory immune response in patients with COVID-19 through the interaction
between the inflammasome and SARS-CoV-2.
2. Inflammasome Complex during Viral Infection
Multiple internal or external stimuli, including bacterial and viral infection, can acti-
vate the intracellular immune complex called the inflammasome, which is comprised of
pattern recognition receptors (PRRs) such as absent in melanoma 2 (AIM2)-like receptor
(ALR) and NLR, the adaptor protein apoptosis-associated speck-like protein containing
a CARD (ASC), and pro-caspase-1 [10]. In particular, upon viral infection, ALR or NLR
families, including NLRP1, NLRP2, NLRP3, and AIM2, detect pathogen-associated molec-
ular patterns (PAMPs) and assemble an intracellular inflammasome complex by recruiting
ASC and pro-caspase-1 [12,13]. This innate immune complex exerts antiviral properties
by eradicating invading viruses, a process that plays a pivotal role in the host defense
system [10]. In the case of the NLRP3 inflammasome complex, two steps are required for
priming and activation. The priming step is triggered by the activation of receptors due to
viral infection, including toll-like receptors (TLRs) and RIG-I-like receptors (RLRs). The
viral infection initiates the intracellular nuclear factor kappa-light-chain enhancer of the
activated B cells (NF-κB) signalling pathway, which contributes to NLRP3, IL-1B, and IL-18
expressions [10,14]. The activation step is initiated by various intra/extracellular stimuli,
ranging from adenosine triphosphate (ATP), reactive oxygen species (ROS), lysosomal
destabilisation, invading pathogens, viral infection-induced alteration in plasma mem-
brane integrity, and ion fluxes [10,14]. The NLRP3 inflammasome assembles with ASC and
pro-caspase-1, thereby leading to the cleavage of caspase-1. This active cleaved caspase-1
promotes IL-1β and IL-18 maturation and the cleavage of gasdermin D (GSDMD) [15].
Cleaved GSDMD (GSDMD Nterm) forms transmembrane pores that allow IL-1β and IL-18
to be secreted into the extracellular environment, which leads to pyroptosis, a lytic type
of cell death [16] (Figure 1). Activation of canonical inflammasome and caspase-1, and
the non-canonical inflammasome and caspase-11 (caspase-4/5 in humans) are responsible
for pyroptosis [14]. In non-canonical inflammasome activation, caspase-11 responds to
intracellular lipopolysaccharide (LPS) from Gram-negative bacteria; LPS in the cytosol
binds to the CARD motif of caspase-11, resulting in the oligomerisation of caspase-11 that
activates the non-canonical inflammasome [17]. Caspase-11 is involved in the cleavage
of GSDMD, and caspase-11-cleaved GSDMD triggers the formation of membrane pores,
which causes potassium efflux, further leading to NLRP3 inflammasome-related caspase-1
activation [18]. Under infectious conditions, inflammasome complex activation leads to
pyroptosis of infected cells that secrete damage-associated molecular patterns (DAMPs),
thereby leading to inflammatory responses [13]. However, abnormal activation or dys-
regulation of the inflammasome complex can exacerbate the host condition, resulting in
pathological injury such as that caused by increased levels of inflammatory cytokines and
cellular and tissue damage [14,15].
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Figure 1. Possible routes of SARS-CoV-2 to activate the inflammasome complex. SARS-CoV-2 enters the cell via the angi-
otensin-converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2). SARS-CoV-2 itself may activate 
the nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) signalling pathway, and NF-κB subunits are 
involved in the expressions of NLRP3, IL-1B, and IL-18. SARS-CoV-2 viroporin might activate the NLRP3 inflammasome 
complex. The NLRP3 inflammasome assembles with the adaptor protein ASC and pro-caspase-1. Inflammasome activa-
tion is responsible for the cleavage of caspase-1 and the promotion of IL-1β and IL-18 secretion. Cleaved caspase-1 results 
in the cleavage of gasdermin D (GSDMD). Cleaved GSDMD creates transmembrane pores, and IL-1β and IL-18 are se-
creted into the extracellular environment, ultimately leading to pyroptosis. 
3. Inflammasome Complex and SARS-CoV-2 Infection in COVID-19 Patients 
The SARS-CoV-2 S protein uses the angiotensin-converting enzyme 2 (ACE2) recep-
tor as an entry receptor and transmembrane serine protease 2 (TMPRSS2) to cleave the S-
protein in order to gain entry into the host cells [19]. SARS-CoV-2 infection is implicated 
in the activation of NF-κB signalling, which is known to initiate the transcription of a va-
riety of genes such as TNF-α, IL-1β, IL-6, IL-8, and monocyte chemoattractant protein-1 
(MCP-1), which are responsible for innate and adaptive immune responses [20]. In addi-
tion, the SARS-CoV-2 S1 protein is involved in the production of IL-1β, IL-6, IL-8, and 
TNF-α in human peripheral blood mononuclear cells (PBMCs); the S1 protein also triggers 
NF-κB signalling by phosphorylation of p65 and IκBα and the degradation of IκBα [9]. 
Similarly, the SARS-CoV-2 S1 protein alone has been related to the increased levels of NF-
κB and IL-1β, and it provokes the cytokine storm by eliciting TNF-α, IL-1β, IL-6, and IL-
17 in vivo [5]. Moreover, the S1 protein enhances the DNA binding of the NF-κB p65 sub-
unit in the nucleus [9] (Figure 1). In the case of SARS-CoV, analogous to the SARS-CoV-2, 
the open reading frame 8b (ORF8b) forms insoluble aggregates and is involved in the ac-
tivation of the NLRP3 inflammasome [21]. In addition, SARS-CoV viroporin 3a promotes 
the activation of the NLRP3 inflammasome and the secretion of IL-1β [22]. The interplay 
between ACE2 and SARS-CoV-2 also triggers the NLRP3 inflammasome [23]. The SARS-
CoV-2 S protein was recently shown to prime inflammasome formation and drive NLRP3 
inflammasome activation in macrophages derived from patients with COVID-19 [8]. The 
SARS-CoV-2 S1 protein increases the NLRP3 level and caspase-1 activity in human 
PBMCs [9]. Uncontrolled responses of monocytes and macrophages to SARS-CoV-2 infec-
tion may be the key source of the hyper-inflammatory response in the circulation [24,25]. 
Figure 1. Possible routes of SARS-CoV-2 to activate the inflammasome complex. SARS-CoV-2 enters the cell via the
angiotensin-converting enzyme II (ACE2) and transmembrane serine protease 2 (TMPRSS2). SARS-CoV-2 itself may activate
the nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) signalling pathway, and NF-κB subunits are
involved in the expressions of NLRP3, IL-1B, and IL-18. SARS-CoV-2 viroporin might activate the NLRP3 inflammasome
complex. The NLRP3 inflammasome assembles with the adaptor protein ASC and pro-caspase-1. Inflammasome activation
is responsible for the cleavage of caspase-1 and the promotion of IL-1β and IL-18 secretion. Cleaved caspase-1 results in the
cl avage f gasdermin D (GSDMD). Cleaved GSDMD creates transmembrane pores, and IL-1β and IL-18 are secreted into
the extracellular environment, ultimately leading to pyroptosis.
3. Inflammasome Complex and SARS-CoV-2 Infection in COVID-19 Patients
The SARS-CoV-2 S protein uses the angiotensin-converting enzyme 2 (ACE2) recep-
tor as an entry receptor and transmembrane serine protease 2 (TMPRSS2) to cleave the
S-protein in order to gain entry into the host cells [19]. SARS-CoV-2 infection is impli-
cated in the activation of NF-κB signalling, which is known to initiate the transcription
of a variety of genes such as TNF-α, IL-1β, IL-6, IL-8, and monocyte chemoattractant
protein-1 (MCP-1), which are responsible for innate and adaptive immune responses [20].
In addition, the SARS-CoV-2 S1 protein is involved in the production of IL-1β, IL-6, IL-8,
and TNF-α in human peripheral blood mononuclear cells (PBMCs); the S1 protein also
triggers NF-κB signalling by phosphorylation of p65 and IκBα and the degradation of
IκBα [9]. Similarly, the SARS-CoV-2 S1 protein alone has been related to the increased
levels of NF-κB and IL-1β, and it provokes the cytokine storm by eliciting TNF-α, IL-1β,
IL-6, and IL-17 in vivo [5]. Moreover, the S1 protein enhances the DNA binding of the
NF-κB p65 subunit in the nucleus [9] (Figure 1). In the case of SARS-CoV, analogous
to the SARS-CoV-2, the open reading frame 8b (ORF8b) forms insoluble aggregates and
is involved in the activation of the NLRP3 inflammasome [21]. In addition, SARS-CoV
viroporin 3a promotes the activation of the NLRP3 inflammasome and the secretion of
IL-1β [22]. The interplay between ACE2 and SARS-CoV-2 also triggers the NLRP3 inflam-
masome [23]. The SARS-CoV-2 S protein was recently shown to prime inflammasome for-
mation and drive NLRP3 inflammasome activation in acrophages derived from patients
with CO ID-19 [8]. The SARS-CoV-2 S1 protein increases the NLRP3 level and caspase-1
activity in huma PBMCs [9]. Uncontrolled responses of monocytes and macr phages to
SARS-CoV-2 infection may be the key source of the hyper-i flammatory response in the
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circulation [24,25]. Interestingly, SARS-CoV-2 RNA provokes an inflammatory response
more than that caused by SARS-CoV-1 RNA [26]. Intensive care unit (ICU) patients in
Wuhan, China who contracted pneumonia after SARS-CoV-2 infection showed high levels
of cytokines in their plasma, including IL-2, IL-7, TNF-α, and MCP-1 [27]. Recent studies
have demonstrated the potential role of the inflammasome complex during the COVID-19
cytokine storm [7,28], and the amount of clinical evidence showing a link between the
inflammasome complex and COVID-19 is increasing. A recent study reported the direct
involvement of the inflammasome complex in COVID-19 [7]. Patients with COVID-19
show high concentrations of active/cleaved caspase-1 and IL-18 in their sera. Concomi-
tantly, the levels of cytokines such as IL-4, IL-6, and IL-10 are also increased in the sera
of patients with COVID-19 compared with those of controls. PBMCs from patients with
COVID-19 exhibit active intracellular caspase-1, increased expressions of NLRP3 and ASC,
and the secretion of IL-1β [7]. Furthermore, primary human monocytes after infection with
SARS-CoV-2 exhibit caspase-1 activation and IL-1β production by inducing NLRP3 inflam-
masome activation [7]. SARS-CoV-2-infected cells undergo pyroptosis and secrete DAMPs,
including ASC oligomers [2]. In addition, SARS-CoV-2 infection has caused pyroptosis-
induced lytic cell death in human primary monocytes, a process that may contribute to the
exacerbated inflammatory response and leukocytopenia observed in patients with severe
COVIID-19 [28]. In particular, SARS-CoV-2 infection triggers the inflammasome complex
in monocytes, inducing the cleavage of caspase-1, IL-1β production, and the cleavage
of GSDMD, an executioner of pyroptosis [28]. Clinically, circulating monocytes isolated
from patients with severe COVID-19 exhibit increased caspase-1 activation and higher
levels of lytic cell death compared with monocytes from healthy controls [28]. Higher
IL-1β levels are observed in the plasma of severely ill patients with COVID-19 [28]. The
SARS-CoV-2 S protein promotes NLRP3 inflammasome activation and IL-1β secretion in
COVID-19 patient-derived macrophages, and stimulation of the S protein upregulates both
IL-1β and TNF-α; however, TNF-α is secreted in an NLRP3 inflammasome-independent
manner [8]. In RNA sequencing, the SARS-CoV-2 S protein is observed to upregulate innate
immunity-associated genes and several signalling pathways, including pro-inflammatory
pathways, the NOD-like receptor, and the inflammasome signalling pathway. In particular,
the S protein increases TLR2 in CD14+ macrophages, and the S protein is correlated with a
high level of TLR2 in cells derived from patients with COVID-19 [8]. In a single-cell RNA
sequencing analysis, the upregulation of caspase expression in immune cells is observed in
blood from patients with COVID-19. In particular, caspase-1 expression is distinct in CD4+
T lymphocytes in hospitalized patients with COVID-19. In addition, an increased IL-18
level is found in the sera of hospitalized patients with COVID-19 [29]. An epigenome-wide
association study showed that DNA methylation participates in the immune response to
COVID-19, and the DNA methylation of 44 CpG sites were associated with inflamma-
somes, interleukins, cytokines, and the major histocompatibility complex (MHC), which
are all relevant to COVID-19 severity [30]. In particular, epigenetic loci are found in the
AIM2 and MHC class I, C (HLA-C) genes [30]. Consistent with these findings, the levels
of inflammasome-associated cytokines, including IL-1β and IL-18, were increased in the
sera of patients with COVID-19 in the ICU [31]. Therefore, the NLRP3 inflammasome in
myeloid cells has been proposed as a biomarker of COVID-19 severity [31].
Previous reports have suggested this relationship with the inflammasome complex
not only in immune cells but also in other types of cells [32,33]. SARS-CoV-2 infection
upregulates the genes involved in innate immunity and inflammasomes in human in-
duced pluripotent stem cell (iPSC)-derived lung organoids (LORGs). In the LORGs,
inflammasome-associated genes, including NLRC4, NLRP3, ASC, CASP1 (caspase-1), and
IL-18, and innate immunity-associated genes such as TLR3 and TLR7, are upregulated in
response to SARS-CoV-2 infection. The altered expression of these genes may be respon-
sible for pulmonary inflammation and cell damage/death in the lungs [32]. Damaged
hematopoietic stem and progenitor cells (HSPCs) and endothelial progenitor cells (EPCs)
are found in patients with severe COVID-19 [33]. More specifically, ACE2 and TLR4 are
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highly observed on the extracellular membrane surfaces of HSPCs and EPCs. Stimulation of
the SARS-CoV-2 S protein induces NLRP3 inflammasome activation and cytosolic activity
of caspase-1 in human CD34+ HSPCs and CD34+ CD133+ CD31+ CD144+ EPCs. Moreover,
the level of released lactate dehydrogenase (LDH) is increased in CD34+ cells; however,
blocking the interaction between the S protein and ACE2 by recombinant human ACE2
results in the suppression of the NLRP3 inflammasome and caspase-1 activity. Treatment
with TLR4 inhibitor TAC-242 and MCC950 also exhibits the same effects [33].
4. Failure of the Adaptive Immune Response by Aberrant Inflammasomes in
Response to SARS-CoV-2
Patients with COVID-19 display lymphopenia (CD4+ and CD8+ T lymphocyte de-
ficiency) and reduced interferon (IFN)-γ expression in CD4+ T lymphocytes, which are
responsible for the severity of COVID-19 [34]. It is also reported that most patients with
COVID-19 exhibit some form of immune deficiency, including lymphopenia in 83.2% of
patients, thrombopenia in 36.2% of patients, and leukopenia in 33.7% of patients [35].
Patients with severe COVID-19 show markedly reduced CD4+ and CD8+ T lymphocyte
levels compared to patients with moderate COVID-19, and the blood of patients with
both severe or moderate COVID-19 is deficient in CD4+ CD25+ CD127lo and CD45RA+
regulatory T lymphocytes [34]. Some patients with severe or moderate COVID-19 show
a deficient expression of IFN-γ in CD4+ T lymphocytes, CD8+ T lymphocytes, and NK
cells; however, lower levels of IFN-γ expression by CD4+ T lymphocytes are found in those
with severe rather than moderate COVID-19 [34]. Thus, a decreased amount of circulating
T lymphocytes is consistent with the reduced expression of IFN-γ. In particular, CD3+
CD4+ helper T (Th) cells and CD3+ CD8+ suppressor T cells were detected below normal
levels in patients with COVID-19, and CD3+ CD4+ CD45RO+ memory Th cells and CD3+
CD8+ CD28+ cytotoxic suppressor T cells were found to be decreased in severe COVID-19
patients as compared to non-severe patients in Wuhan, China [36]. These findings support
that COVID-19 recovery is implicated in memory formation in T cells [37]. Inflammasome
activation leads to immune disturbance and lymphopenia, which are linked to adaptive
immune system failure [38]. Inflammasome activation is responsible for pyroptotic T cell
death, which may drive T-cell lymphopenia [38]. In one clinical study, high activity of
caspase-1 was detected in CD3+ CD4+ CD45+ T cells and CD3+ CD45+ T cells, and in-
creased levels of lactate dehydrogenase, a marker of pyroptosis, and IL-18 were observed in
COVID-19 patients. In the lethal course of COVID-19, individuals with T-cell lymphopenia
have been found to be more susceptible to pathological outcomes [38]. Inflammasome-
induced pyroptosis of T cells results in the suppression of the adaptive immune system
and the induction of the inflammatory response. In addition, abnormal distribution and
dysregulated innate immune cells have an effect on the adaptive immune response. For in-
stance, circulating myeloid cells show distinct phenotypes, i.e., a reduction of non-classical
monocytes [39]. In COVID-19, an aberrant monocyte compartment is observed in a time-
and severity-dependent manner [40]. All patients with COVID-19 exhibited a marked
reduction of the CD14lo CD16hi non-classical monocyte. Patients with mild COVID-19
show increased levels of HLA-DRhi CD11chi/HLA-DRhi CD83hi inflammatory monocytes.
Additionally, dysfunctional mature neutrophils and HLA-DRlo monocytes are observed in
patients with severe COVID-19 [40]. Taken together, the abnormal distribution and number
of immune cells as well as the dysregulated communication between innate and adap-
tive immune cells due to aberrant inflammasomes and insufficient/deficient lymphocytes
caused by pyroptotic cell death may contribute to an abnormal adaptive immune response.
5. Involvement of Inflammasomes in SARS-CoV-2-Derived Organ Damage in Patients
with COVID-19 and Comorbidities
The cytokine storm is implicated in the tissue injury observed in patients with severe
COVID-19 [41]. SARS-CoV-2 can damage many organs in the body, including the lungs,
liver, kidneys, and heart as well as the blood, resulting in death due to multiple organ
failure [42]. Furthermore, the presence of comorbidities in patients with COVID-19 is
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implicated in poor clinical outcomes, with these patients having a higher risk of mortal-
ity [43,44]. Many patients with COVID-19 have at least one underlying disease such as
diabetes, hypertension, cerebrovascular disease, chronic renal diseases, or coronary heart
disease [35]. Recently, autopsies of children and adolescents with COVID-19 revealed that
SARS-CoV-2 had infected their lungs, kidneys, and hearts [45]. The patients exhibited
pulmonary diseases with severe acute respiratory disease or multi-system inflammatory
syndrome [45].
Damages to organs including the brain, kidney, muscle, and spleen—acute tubular
necrosis and congestion in the kidney; splenitis, haemorrhages, and lymphoid hypoplasia in
the spleen; reactive microglia, neuronal ischemia, and congestion in the brain; and myolysis
and necrotic fibers in the muscles—were observed in patients with COVID-19 [45]. From the
COVID-19 autopsies, marked vascular changes were observed in the blood vessels, which
are known to express ACE2 on the surface of endothelial cells in the vascular system [46].
The blood vessels had severe phenotypes such as pulmonary arterial thromboemboli,
deep vein thrombosis, and hypercoagulability [46]. The autopsies of 23 patients with
COVID-19 showed severe capillary fibrin deposition, micro-haemorrhage, and capillary
dilation in the myocardium [47]. These patients had comorbidities, including hypertension,
coronary artery diseases, and diabetes mellitus [47]. In some cases, elevated interstitial
CD68+ macrophage numbers were reported [47]. Moreover, patients with COVID-19
showed distinct hepatic symptoms [48]. Aberrant hepatic enzymes, hyperplasia, platelet-
fibrin microthrombi, lobular inflammation, ischaemic hepatic necrosis, and steatosis were
observed in the post-mortem livers of patients with COVID-19 [48]. One of the major causes
of death of patients with COVID-19 was respiratory failure [49]. In particular, interstitial
fibrosis and diffuse alveolar damage due to the disruption of the blood–air barrier and
the infiltration of immune cells in the lungs were found in the autopsies of patients with
COVID-19 [49]. Among 26 COVID-19 cases, 20 had pre-existing diseases such as chronic
cardiovascular diseases (38.5%), hypertension (34.6%), and chronic pulmonary diseases
(23.1%) [49]. Post-mortem lung tissues from patients with COVID-19 exhibit enormously
increased numbers of NLRP3 and ASC-positive cells compared to those of control lung
tissues [7]. Similarly, inflammasome components, including NLRP3, ASC specks, and
caspase-1, are found in leukocytes of post-mortem lung samples of patients with fatal
cases of COVID-19 [50]. In addition, elevated macrophage infiltration and ASC speck
formation are observed in post-mortem lungs of patients with COVID-19 [51]. Patients
with COVID-19 develop a highly severe fibrotic response in the lung, and patients with
idiopathic pulmonary fibrosis (IPF) are at high risk of severe COVID-19 [52]. Interestingly,
NLRP3 inflammasome is directly involved in lung fibrosis [53]. Exogenous IL-1β induces
lung inflammation, alveolar tissue destruction, tissue remodelling, and fibrosis [54], and a
high level of IL-18 is detected in IPF [55].
Individuals with pre-existing diseases are more susceptible to SARS-CoV-2 infec-
tion and often have negative outcomes [44,56,57]. The inflammasome may induce acute
inflammatory responses in patients with pre-existing conditions suffering from chronic
inflammation [38]. Patients with non-alcoholic fatty liver disease, liver cirrhosis, or patients
that have undergone a liver transplant display higher levels of IL-18 and LDH in the
liver and increased levels of caspase-1 in T lymphocytes [38]. Moreover, patients with
pre-existing cardiovascular diseases may be vulnerable to COVID-19 [58]. RNA sequencing
reveals that patients with non-ischaemic dilated cardiomyopathy or ischaemic cardiomy-
opathy and patients with COVID-19 share dysregulated immune-associated genes such
as ILs and chemokine ligands (CCLs), and NF-κB-associated genes such as IKBKG and
NFKBIA [58]. More importantly, the upregulation of inflammasome-associated genes and
inflammatory macrophages are observed in patients with cardiomyopathy and patients
with COVID-19 [58]. Moreover, the RNA sequencing of PBMCs from patients with coronary
artery diseases displays a similar pattern of immune-associated gene expressions compared
to that from patients with COVID-19 [58]. Interestingly, inflammasome-associated genes
such as CHUK and NFKBIA are dysregulated in both patients [58]. These results sug-
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gest that immune dysregulation observed in underlying diseases exacerbates COVID-19
severity, and patients with pre-existing diseases are susceptible to severe COVID-19 [38,58].
6. Consideration of Targeted Therapies
Many patients with COVID-19 die of immunomodulatory failure and organ damage
due to SARS-CoV-2-induced pneumonia, ARDS, or CRS [1,3,4]. Immune-modulating ther-
apies will be required in the COVID-19 pandemic to conquer SARS-CoV-2. Inflammasome-
driven caspase-1 activation and IL-1β production after SARS-CoV-2 infection can be sup-
pressed by treatment with MCC950, a selective inhibitor of NLRP3 in primary human
monocytes [7]. Furthermore, SARS-CoV-2-induced lytic cell death is reversed by the
diabetes medicine glyburide, which abolishes the activation of the NLRP3 inflamma-
some. Enhanced IL-1β production due to SARS-CoV-2 infection has been shown to be
inhibited by treatment with the caspase-1 inhibitor AC-YVAD-CMK or pan-caspase in-
hibitor Z-VAD-FMK [28]. Metformin, an anti-diabetic, inhibits the SARS-CoV-2-induced
pulmonary inflammatory response, which diminishes immune cell recruitment and ASC
speck formation in SARS-CoV-2-infected mice [51]. The pan-caspase inhibitor emricasan
inhibited the caspase-1 activity of CD4+ T lymphocytes in the blood of patients with
moderate to severe COVID-19 [29]. Moreover, pre-treatment with dexamethasone or an
NF-κB inhibitor BAY-11-7082 suppresses the phosphorylation of NF-κB p65 and IκBα,
thereby inhibiting the translocation of NF-κB p65 to the nucleus and the DNA binding
of p65 in human PBMCs stimulated by the SARS-CoV-2 S1 protein [9]. The overproduc-
tion of IL-1β is attenuated in SARS-CoV-2 S1 protein-stimulated human PBMCs treated
with dexamethasone [9]. Although pre-treatment with dexamethasone slightly reduces
NLRP3, treatment of CRID3 (NLRP3 inhibitor) efficiently attenuates the increasing levels of
NLRP3 and IL-1β as well as the activation of caspase-1 in human PBMCs stimulated by the
SARS-CoV-2 S1 protein [9]. In addition, the SARS-CoV-2-mediated activation of caspase-1
and cell lysis are reversed by the IL-1 receptor antagonist (IL-1RA), while AC-YVAD-CMK
and IL-1RA suppress levels of pro-inflammatory cytokines IL-6 and TNF-α [28]. Both
IL-6 and TNF-α are found in patients with COVID-19 and are responsible for pathological
injury [3]. Similarly, treatment with anakinra, which is a recombinant IL-1RA known to
reduce pro-inflammatory cytokines such as IL-1α and IL-1β, exhibits beneficial effects on
patients with COVID-19 [59]. Treatment with a high-dose of anakinra suppresses hyper-
inflammatory symptoms in patients with COVID-19 and exhibits clinical improvements,
including that of respiratory function [59]. In addition, the S protein inhibitor EK1 peptide
and TMPRSS2 inhibitors such as camostat and nafamostat suppress SARS-CoV-2 entry in
LORGs [32]. S protein-induced inflammasome activation is reversed by treatment with
MCC950, and the release of IL-1β is also blocked in spite of S-protein exposure. Sim-
ilarly, treatment with VX-765 (a caspase-1 inhibitor) suppresses NLRP inflammasome
activation and the secretion of IL-1β [8]. Additionally, the development of nanovesicles
through biomedical engineering may prevent the cytokine storm that occurs in patients
with COVID-19 [60]. For instance, 25-hydroxycholesterol and didodecyldimethylammo-
nium bromide (25-HC@DDAB) nanovesicles are lung-specific and with high efficacy [60].
The 25-HC@DDAB inhibits the cytokine storm in PBMCs derived from patients with
COVID-19. In addition, the mRNA level of the inflammasome component NLRP3 and the
enhanced production of IL-1β are reversed by treatment with 25-HC@DDAB in PBMCs
from patients with severe COVID-19 [60]. Based on the reported data, the inflammasome
may be a key mediator of the cytokine storm and the modulation of the inflammasome
complex may help us understand the pathogenic mechanisms of SARS-CoV-2 and discover
new promising therapeutics. Although there are no clinical trials or observations for these
potential therapeutic candidates until now, they may be tested and applied in clinical
practice. Additionally, it is also important to test any treatments in clinical application for
toxicity and efficacy.
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7. Conclusions
Some patients with COVID-19 display poor clinical outcomes and experience a cy-
tokine storm, which can lead to multiple organ damage and death. The inflammasome
appears to contribute to this immune disturbance. The importance of the inflammasome is
emerging these days. SARS-CoV-2 can trigger inflammasome activation and the release of
pro-inflammatory cytokines (Table 1). Inflammasome components and cytokines can be
observed in the plasma or sera from patients with COVID-19 as well as in post-mortem
specimens. They appear to have a detrimental effect. However, several in vitro studies
have demonstrated that the regulation of the inflammasome has a protective effect against
SARS-CoV-2 infection by reducing inflammasome activation, inflammasome-driven cy-
tokine levels, or SARS-CoV-2-induced lytic cell death. Although little is known about the
interaction between inflammasome and SARS-CoV-2, it suggests that the inflammasome
and its regulation have the potential as therapeutic targets for patients with COVID-19.
Table 1. Abnormal inflammasome activation after SARS-CoV-2 infection.
Materials Abnormal Inflammasome Activation References
Human
Primary human monocytes
• SARS-CoV-2-induced NLRP3 inflammasome
activation, caspase-1 activation, IL-1β
production, and pyroptosis
[7]
• SARS-CoV-2-driven NLRP3 inflammasome
activation, IL-1β production, lytic cell death,
and increased LDH levels
[28]
Human peripheral blood mononuclear cells
(PBMCs)
• Increased levels of NLRP3 and ASC, and
active intracellular caspase-1
[7]
• SARS-CoV-2 S1 protein-induced NF-κB
activation, NLRP3 inflammasome, caspase-1
activation, and increased levels of IL-1β
[9]
Supernatants from PBMCs • High level of IL-1β [7]
Human macrophage
• SARS-CoV-2 S protein-driven activation of
inflammasome and secretion of IL-1β
[8]
Human serum
• High concentration of Casp1p20 and IL-18 in
patients with COVID-19
[7]
• Inflammasome-induced increased levels of
IL-1β and IL-18 in patients with COVID-19 [31]
Postmortem lung tissue
• High number of NLRP3 and ASC puncta in
patients with COVID-19 [7]
• Higher levels of NLRP3, ASC specks, and
caspase-1 in leukocytes in the lungs from
patients with COVID-19
[50]
Human hematopoietic stem cells (HSCs)
• SARS-CoV-2 S protein-induced activation of
NLRP3 inflammasome [23]
• SARS-CoV-2 S protein-induced NLRP3
inflammasome activation and cytosolic
activity of caspase-1
[33]
Very small embryonic-like stem cells (VSELs)
• SARS-CoV-2 S protein-induced activation of
NLRP3 inflammasome [23]
Endothelial progenitor cells (EPCs)
• SARS-CoV-2 S protein-induced NLRP3




• SARS-CoV-2 S1 subunit-triggered NF-κB
signalling and IL-1β release [5]
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